9 Ha’Ta’asiya Street
About UroGenUroGen Pharma (“UroGen” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC. In addition, UroGen is developing an additional clinical-stage drug candidate, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer. The company has recently licensed BotuGel for the treatment of overactive bladder and interstitial cystitis, to Allergan for further development.
CEO: Ron Bentsur
CFO: Gary Titus
Please click here for clinical trial information.
44 articles with UroGen
UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, announced that it will present at the following conference in October
UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness
Company to Also Participate in September Investor Conferences
Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization.
UroGen Pharma Ltd., announced that management will present at three investor conferences in June
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
UroGen Pharma Ltd. announced financial results for the first quarter ended March 31, 2019 and provided an overview of the Company’s recent developments.
Quite a few companies recently released results from late-stage clinical trials. Here’s a look at some of the top stories, from AveXis, Urovant, Lilly, and more.
UroGen Pharma Ltd. announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market.
Focused Agreement is on Therapeutic Area of Mutual Interest
UroGen Pharma Ltd., announced that management will present at two investor conferences in March
Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020
UroGen Pharma Ltd. today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering.
UroGen Pharma, based in New York, announced positive topline results from its Phase III OLYMPUS clinical trial. The trial evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC).
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Ms. Barrett Most Recently Served as CEO for Novartis Oncology and Brings a Track Record of Success in Commercial Oncology
Novartis and Pfizer veteran Elizabeth Barrett will take over as the new president and chief executive officer of UroGen Pharma Ltd. Barrett, who most recently helmed Novartis Oncology, will take over as Ron Bentsur steps down from his role as CEO.
UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
UGN-101 Has the Potential to Become the First Drug Ever Approved for LG UTUC
UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment
Following a Recent Pre-New Drug Application Meeting with the FDA for UGN-101, the Company Has Concluded Patient Enrollment in the OLYMPUS Phase 3 Trial for Low-Grade Upper Tract Urothelial Cancer
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
UroGen Pharma Ltd. today announced that management will present at two investor conferences in November 2018